1. Scrip
  3. >>Strategy

Novartis Leqvio Launch Lags As COVID-19 Hinders England Access Scheme

Swiss Giant Waiting For Moratorium To Be Lifted

 
• By Kevin Grogan

The CEO and head of pharma at Novartis have both cautioned against expectations of a lucrative launch for Leqvio, saying that a completely new approach to treating cholesterol lowering with a vaccine-like approach of administration twice a year will take time to get established in healthcare systems.

Novartis HQ
• Source: Novartis

Anyone expecting to see Novartis's Leqvio come flying out of the blocks got a dose of reality as the Swiss major gave an update on the launch of the closely watched cholesterol-lowering drug that revealed a stuttering start to a landmark population-based agreement in England.

In September last year, some 20 months after unveiling an alliance with NHS England to give at-risk patients speedy access to Leqvio (inclisiran), Novartis secured reimbursement in the country for the first-in-class small-interfering RNA (siRNA) drug that inhibits synthesis of PCSK9 which could be used to treat hundreds of thousands of cardiovascular patients

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By Joseph Haas

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Deal Watch: Lilly Looks To Creyon For Oligonucleotides

 
• By Joseph Haas

Plus deals involving J&J/Addex/Sinntaxis, Concentra/Kronos, Granata/Oviva, Coeptis/Z Squared, Ligand/Channel and more.

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

 
• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

More from Business